Nearly every successful single-location operator eventually reaches the same fork in the road. Demand is there, the model works, and the obvious next move is a second site. What isn't obvious is how to get one. You can build it from scratch — a de novo location — or you can buy one that already exists. Both paths can be right. They fail for different reasons, they reward different strengths, and the worst outcomes usually come from choosing on instinct and building the financial case afterward.
The two options have fundamentally different risk shapes, and understanding that shape is where the decision starts.
Two different risk shapes
A de novo build carries a lower purchase cost but higher execution risk and a longer ramp. You control the site selection, the layout, the brand experience, and who you hire — but you fund the losses while the location fills up. That funded loss period is real money, and it is the number most operators underestimate.
An acquisition inverts the trade. You pay a premium for revenue and cash flow that already exist, which shortens the path to contribution dramatically. But you inherit someone else's decisions: their compensation agreements, their deferred maintenance, their lease terms, their systems, and their culture. You are buying a running business, and running businesses have baggage that only surfaces when you look closely.
What a de novo build actually costs
The opening budget — build-out, equipment, initial licensing — is the part everyone models. The part that sinks projects is the cumulative cash trough: the total losses accumulated before the location reaches breakeven. A site that turns cash-flow positive in, say, month twelve (an illustrative figure, not a promise) will still have consumed many months of rent, payroll, and overhead on the way there. You are not funding a single monthly loss; you are funding the sum of every month until breakeven, plus a buffer for the ramp running slower than planned.
In healthcare specifically, one line item deserves its own attention: the lag between opening the doors and being credentialed with payers. Revenue can be effectively frozen for weeks or months while enrollment processes complete, even as payroll runs in full. Modeling that gap honestly is the difference between a plan and a hope. This is exactly the kind of scenario where disciplined FP&A and forecasting earns its keep, and where our healthcare CFO work tends to concentrate.
What an acquisition actually costs
The purchase price — often expressed as a multiple of earnings — is only the visible cost. The real cost includes transition expenses, the retention of key people, systems integration, and the work of normalizing the seller's numbers. A price that looks like a reasonable multiple can climb sharply once you adjust for below-market owner compensation, deferred capital spending the seller postponed, and revenue that may leave with the departing owner or a departing provider.
This is why buy-side diligence is not a formality. Understanding the quality of the earnings you are buying — how repeatable they are, how much depends on one relationship — is the core of protecting the price. Our M&A and transaction support work exists largely to answer that question before the money moves.
A framework for comparing the two
Rather than argue the paths in the abstract, score each option against the same five dimensions:
- Capital required — the total cash at risk, including the funded loss period for a build or the integration budget for a buy.
- Time to contribution — how long until the location adds to cash flow rather than draining it.
- Control — greenfield freedom to design the operation versus inherited constraints you must live with or unwind.
- Type of risk — execution and demand risk on a build; diligence and integration risk on a buy.
- Strategic fit — whether the move is about entering a market, acquiring talent, or defending a position.
A build and a buy that look equivalent on price are almost never equivalent across these five. Forcing both into the same scorecard makes the real trade-off visible.
The questions that usually decide it
A few questions tend to settle the matter faster than any spreadsheet. Do you have proven, overflowing demand you simply cannot serve today — or are you betting on demand you will have to create? The first favors a build; the second raises the risk of one. Is the target's value in its cash flow, or in its people? If the answer is people, retention structures matter more than the headline price. And does your capital structure tolerate a funded loss period, or does it prefer a larger check up front with faster returns?
Model both to the same standard
Whichever way you lean, build the case in one consistent model: cumulative cash, breakeven timing, and sensitivity to the two variables most likely to move — ramp speed for a build, retention for a buy. Treating a second location as a discrete project with its own economics, rather than a rounding error inside the parent P&L, is the discipline that separates confident expansion from expensive improvisation. For operators running several of these decisions at once, formal financial project management keeps each one honest, and sponsor-backed groups will recognize this as the same rigor expected in a private-equity value-creation plan.
There is no universal winner. The build rewards operators with proven demand and the patience to fund a ramp. The acquisition rewards those buying cash flow or talent they can actually retain — provided they have the discipline to diligence what they are inheriting. Choose the path that fits your demand, your capital, and your appetite for the specific risk each one carries. Just make the choice with both models on the table, not one.